SANUWAVE Health (SNWV) 10-K 31 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Mar. 23, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	SANUWAVE Health, Inc.
Entity Central Index Key	1,417,663
Trading Symbol	snwv
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		138,815,329
Entity Public Float			$ 3.8
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
CURRENT ASSETS
Cash and cash equivalents	$ 133,571	$ 152,930
Accounts receivable, net of allowance for doubtful accounts of $35,196 in 2016 and $8,963 in 2015	460,799	74,454
Inventory (Note 3)	231,953	284,908
Prepaid expenses	87,823	123,988
TOTAL CURRENT ASSETS	914,146	636,280
PROPERTY AND EQUIPMENT, at cost, less accumulated depreciation (Note 4)	76,938	4,228
OTHER ASSETS	13,786	11,097
INTANGIBLE ASSETS, at cost, less accumulated amortization (Note 5)		306,756
TOTAL ASSETS	1,004,870	958,361
CURRENT LIABILITIES
Accounts payable	712,964	509,266
Accrued expenses (Note 6)	375,088	359,374
Accrued employee compensation	64,860	241,542
Interest payable, related parties (Note 7)	109,426	239,803
Short term loan, net (Note 8)	47,440
Warrant liability (Note 12)	1,242,120	138,100
Notes payable, related parties, net (Note 7)	5,364,572
TOTAL CURRENT LIABILITIES	7,916,470	1,488,085
NON-CURRENT LIABILITIES
Notes Payable, Related Parties, Noncurrent		5,348,112
TOTAL LIABILITIES	7,916,470	6,836,197
COMMITMENTS AND CONTINGENCIES (Note 13)
Preferred stock	137,220	63,057
ADDITIONAL PAID-IN CAPITAL	92,436,697	87,086,677
ACCUMULATED DEFICIT	(99,433,448)	(92,994,408)
ACCUMULATED OTHER COMPREHENSIVE LOSS	(52,069)	(33,162)
TOTAL STOCKHOLDERS' DEFICIT	(6,911,600)	(5,877,836)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,004,870	958,361
Series A Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock
Series B Convertible Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock
Undesignated Preferred Stock [Member]
NON-CURRENT LIABILITIES
Preferred stock

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accounts receivable, allowance for doubtful accounts	$ 35,196	$ 8,963
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	137,219,968	63,056,519
Common stock, shares outstanding (in shares)	137,219,968	63,056,519
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	293	293
Preferred stock, shares issued (in shares)	293	293
Preferred stock, shares outstanding (in shares)	0	0
Undesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	4,993,532	4,993,532
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
REVENUES	$ 1,376,063	$ 965,501
COST OF REVENUES (exclusive of depreciation and amortization shown below)	565,129	284,962
OPERATING EXPENSES
Research and development	1,128,640	2,172,819
General and administrative	2,673,773	2,735,129
Depreciation	19,858	3,612
Amortization of Intangible Assets	306,756	306,757
Gain of sale of assets, property and equipment	(1,594)	(100,000)
TOTAL OPERATING EXPENSES	4,127,433	5,118,317
OPERATING LOSS	(3,316,499)	(4,437,778)
OTHER INCOME (EXPENSE)
Gain (loss) on warrant valuation adjustment and conversion	(2,223,718)	58,515
Interest expense, net	(854,980)	(399,832)
Amortization of debt discount	(31,514)	(12,358)
Loss on foreign currency exchange	(12,329)	(18,832)
TOTAL OTHER INCOME (EXPENSE), NET	(3,122,541)	(372,507)
NET LOSS	(6,439,040)	(4,810,285)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(18,907)	(20,685)
TOTAL COMPREHENSIVE LOSS	$ (6,457,947)	$ (4,830,970)
LOSS PER SHARE:
Net loss - basic and diluted (in dollars per share)	$ (0.06)	$ (0.08)
Weighted average shares outstanding - basic and diluted (in shares)	107,619,869	63,025,202

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Deficit - USD ($)	Series A Warrants [Member]Preferred Stock [Member]	Series A Warrants [Member]Common Stock [Member]	Series A Warrants [Member]Additional Paid-in Capital [Member]	Series A Warrants [Member]Retained Earnings [Member]	Series A Warrants [Member]AOCI Attributable to Parent [Member]	Series A Warrants [Member]	Cash Exercise Warrants [Member]Preferred Stock [Member]	Cash Exercise Warrants [Member]Common Stock [Member]	Cash Exercise Warrants [Member]Additional Paid-in Capital [Member]	Cash Exercise Warrants [Member]Retained Earnings [Member]	Cash Exercise Warrants [Member]AOCI Attributable to Parent [Member]	Cash Exercise Warrants [Member]	Cashless Exercise Warrants [Member]Preferred Stock [Member]	Cashless Exercise Warrants [Member]Common Stock [Member]	Cashless Exercise Warrants [Member]Additional Paid-in Capital [Member]	Cashless Exercise Warrants [Member]Retained Earnings [Member]	Cashless Exercise Warrants [Member]AOCI Attributable to Parent [Member]	Cashless Exercise Warrants [Member]	Warrants Issued for Services [Member]Preferred Stock [Member]	Warrants Issued for Services [Member]Common Stock [Member]	Warrants Issued for Services [Member]Additional Paid-in Capital [Member]	Warrants Issued for Services [Member]Retained Earnings [Member]	Warrants Issued for Services [Member]AOCI Attributable to Parent [Member]	Warrants Issued for Services [Member]	Warrants Issued with Short Term Loan [Member]Preferred Stock [Member]	Warrants Issued with Short Term Loan [Member]Common Stock [Member]	Warrants Issued with Short Term Loan [Member]Additional Paid-in Capital [Member]	Warrants Issued with Short Term Loan [Member]Retained Earnings [Member]	Warrants Issued with Short Term Loan [Member]AOCI Attributable to Parent [Member]	Warrants Issued with Short Term Loan [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]Preferred Stock [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]Common Stock [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]Additional Paid-in Capital [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]Retained Earnings [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]AOCI Attributable to Parent [Member]	Convertible Subordinated Debt [Member]Peak One Convertible Debenture Conversion [Member]	Private Placement [Member]Preferred Stock [Member]	Private Placement [Member]Common Stock [Member]	Private Placement [Member]Additional Paid-in Capital [Member]	Private Placement [Member]Retained Earnings [Member]	Private Placement [Member]AOCI Attributable to Parent [Member]	Private Placement [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2014																																											1,165	60,726,519
Balances at Dec. 31, 2014																																											$ 1	$ 60,727	$ 86,584,472	$ (88,184,123)	$ (12,477)	$ (1,551,400)
Net loss																																														(4,810,285)		(4,810,285)
Preferred stock conversion (in shares)																																											(1,165)	2,330,000
Preferred stock conversion																																											$ (1)	$ 2,330	(2,329)
Stock-based compensation - options																																													504,534			504,534
Foreign currency translation adjustment																																															(20,685)	(20,685)
Balances (in shares) at Dec. 31, 2015																																												63,056,519
Balances at Dec. 31, 2015																																												$ 63,057	87,086,677	(92,994,408)	(33,162)	(5,877,836)
Net loss																																														(6,439,040)		(6,439,040)
Preferred stock conversion (in shares)																																835,000											(293)	3,657,278
Preferred stock conversion																																$ 835	$ 49,265			$ 50,100								$ 3,657	(3,657)
Stock-based compensation - options																																													547,842			547,842
Foreign currency translation adjustment																																															(18,907)	(18,907)
Balances (in shares) at Dec. 31, 2016																																												137,219,968
Balances at Dec. 31, 2016																																												$ 137,220	92,436,697	(99,433,448)	(52,069)	(6,911,600)
Series A Warrant conversion to stock (in shares)	293	7,447,954
Series A Warrant conversion to stock		$ 7,447	$ 880,971			$ 888,418
Equity Offering (in shares)																																						28,300,001						30,016,670
Equity Offering																																						$ 28,300	$ 1,499,900			$ 1,528,200		$ 30,017	1,566,838			1,596,855
Warrant conversion/exercise (in shares)								843,333						2,627,821
Warrant conversion/exercise								$ 843	$ 66,623			$ 67,466		$ 2,628	$ 263,093			$ 265,721
Shares issued for services (in shares)																																												435,392
Shares issued for services																																												$ 436	43,104			43,540
Beneficial conversion feature on debt																																													$ 191,231			$ 191,231
Warrants issued																					$ 186,410			$ 186,410			$ 58,400			$ 58,400

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss) Attributable to Parent	$ (6,439,040)	$ (4,810,285)
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Amortization of Intangible Assets	306,756	306,757
Depreciation	19,858	3,612
Change in allowance for doubtful accounts	26,233	(6,055)
Stock-based compensation - employees, directors and advisors	547,842	504,534
Warrants issued for services	186,410
(Gain) loss on warrant valuation adjustment	2,223,718	(58,515)
Amortization of debt issuance costs	225,786
Stock issued for consulting services	43,540
Amortization of debt discount	31,514	12,358
Gain on sale of asset, property and equipment	(1,594)	(100,000)
Changes in assets - (increase)/decrease
Accounts receivable - trade	(412,578)	18,005
Inventory	(29,249)	(13,037)
Prepaid expenses	36,165	4,562
Other	(2,689)	9
Changes in liabilities - increase/(decrease)
Accounts payable	203,698	277,426
Accrued expenses	15,714	(10,082)
Accrued employee compensation	(176,682)	239,316
Interest payable, related parties	(130,377)	157,939
NET CASH USED BY OPERATING ACTIVITIES	(3,199,453)	(3,473,456)
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from sale of property and equipment	1,594	100,000
Purchases of property and equipment	(10,364)
NET CASH PROVIDED (USED) BY INVESTING ACTIVITIES	(8,770)	100,000
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from 2016 Public Offering, net	1,596,855
Proceeds from 2016 Private Offering, net	1,528,200
Proceeds from short term loan	100,000
Proceeds from warrant exercise	67,466
NET CASH PROVIDED BY FINANCING ACTIVITIES	3,207,771
EFFECT OF EXCHANGE RATES ON CASH	(18,907)	(20,685)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(19,359)	(3,394,141)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	152,930	3,547,071
CASH AND CASH EQUIVALENTS, END OF PERIOD	133,571	152,930
SUPPLEMENTAL INFORMATION
Cash paid for interest, related parties	630,549	242,904
NONCASH INVESTING AND FINANCING ACTIVITIES
Stock issued with convertible debenture	50,100
Stock issued for services	43,540
Loss on warrant conversion to stock	888,418
Beneficial conversion feature on convertible debt	191,231
Warrants issued for services	186,410
Warrants issued for short tem loan	58,400
Convertible Promissory Notes [Member]
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Gain (loss) on conversion of debt	75,422
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible debt	106,000
Payment of convertible debt	(155,750)
NONCASH INVESTING AND FINANCING ACTIVITIES
Beneficial conversion feature on convertible debt	66,331
Convertible Debentures [Member]
Adjustments to reconcile loss from continuing operations to net cash used by operating activities
Gain (loss) on conversion of debt	50,100
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible debt	175,000
Payment of convertible debt	(210,000)
NONCASH INVESTING AND FINANCING ACTIVITIES
Beneficial conversion feature on convertible debt	$ 124,900

Note 1 - Going Concern

Note 1 - Going Concern	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Going Concern As shown in the accompanying consolidated financial statements, SANUWAVE Health, Inc. and Subsidiaries (the “Company”) incurred a net loss of $6,439,040 $4,810,285 December 31, 2016 2015, $3,199,453 $3,473,456, . As of December 31, 2016, $7,002,324, $6,911,600 $133,571 . These factors create an uncertainty about the Company’s ability to continue as a going concern. The Company does not currently generate significant recurring revenue and will require additional capital during or before the second 2017. second 2017. The continuation of the Company’s business is dependent upon raising additional capital during or before the second 2017 2017 may may Although no assurances can be given, management of the Company believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for the Company to continue as a going concern. If these efforts are unsuccessful, the Company may The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of significant accounting policies Description of the business ® two July 2016 2017. Our revenues are generated from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia and Asia/Pacific as we do not currently have any approved devices or accessories to sell in the United States. The significant accounting policies followed by the Company are summarized below: Foreign currency translation 830, Foreign Currency Matters Principles of consolidation Estimates may Cash and cash equivalents 90 may Concentration of credit risk and limited suppliers 50% 32% December 31, 2016, 87% 10% December 31, 2016. 37% 29% December 31, 2015, 63% 10% December 31, 2015. We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may may one may Accounts receivable 60 Inventory first first The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete. Depreciation of property and equipment 3 5 15 3 3 2 Intangible assets 11.4 T he Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may ● Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application; ● Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and ● Significant underperformance of the Company’s assets relative to future operating results. If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value. Fair value of financial instruments The Company has adopted ASC 820 10, Fair Value Measurements The ASC 820 10 one three Level 1 Level 2 1 Level 3 The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities 815 3 The following table sets forth a summary of changes in the fair value of the derivative liability for the year ended December 31, 2016: Warrant Liability Balance at December 31, 2015 $ 138,100 New issuances 34,441 Warrant redemption (1,154,139 ) Change in fair value 2,223,718 Balance at December 31, 2016 $ 1,242,120 The Company’s notes payable, related parties had an aggregate outstanding principal balance of $5,364,572, $8,171 December 31, 2016 $5,348,112, $24,631 December 31, 2015, eight June 15, 2015. 3 $4,923,723 $4,844,792 December 31, 2016 2015, Impairment of long-lived assets may Revenue recognition Shipping and handling costs I ncome taxes 740, Income Taxes . Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. A provision of ASC 740, Income Taxes 48) 740 The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2016 2015, Loss per share 260, Earnings Per Share 260, To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2016 2015, 94,290,134 48,376,071 December 31, 2016 2015, Comprehensive income 220, Comprehensive Income Stock-based compensation 718, Compensation – Stock Compensation 718, three Research and d evelopment third Recent pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09), 2014 09 2014 09 five may December 15, 2017, 2014 09 July 2015, one 2014 09, first 2019 first 2018. August 2015, 2015 14, Revenue from Contracts with Customers (Topic 606) 2014 09 one 2014 09 December 31, 2017, 2014 09 In August 2014, 2014 15, 205 40): December 15, 2016, fourth 2016. In April 2015, 2015 03, Interest-Imputation of Interest (Subtopic 835 30): first December 15, 2015. first 2016. In July 2015, 2015 11, Simplifying the Measurement of Inventory 2015 11), first first 2015 11 first December 15, 2016, 2015 11 January 1, 2016. In November 2015, 2015 17, Income Taxes (Topic 740): Classification of Deferred Taxes December 15, 2016, In February 2016, 2016 02, Leases (Topic 842) December 15, 2018, In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718). December 31, 2016. In August 2016, 2016 15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Topic 230) eight December 15, 2017.

Note 3 - Inventory

Note 3 - Inventory	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Inventory Disclosure [Text Block]	3. Inventory Inventory consists of the following at December 31, 2016 2015: 2016 2015 Inventory - finished goods $ 218,592 $ 290,623 Inventory - parts 89,621 87,450 Gross inventory 308,213 378,073 Provision for losses and obsolescence (76,260 ) (93,165 ) Net inventory $ 231,953 $ 284,908

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment Property and equipment consists of the following at December 31, 2016 2015: 2016 2015 Machines and equipment $ 240,295 $ 240,295 Office and computer equipment 156,860 166,398 Devices 82,204 - Software 34,528 34,528 Furniture and fixtures 16,019 20,380 Other assets 2,259 2,259 Total 532,165 463,860 Accumulated depreciation (455,227 ) (459,632 ) Net property and equipment $ 76,938 $ 4,228 Depreciation expense was $19,858 $3,612 December 31, 2016 2015, 2.

Note 5 - Intangible Assets

Note 5 - Intangible Assets	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	5. Intangible assets Intangible assets consist of the following at December 31, 2016 2015: 2016 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,502,135 ) (3,195,379 ) Net intangible assets $ - $ 306,756 Amortization expense was $306,756 $306,757 December 31, 2016 2015, 2.

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses Accrued expenses consist of the following at December 31, 2016 2015: 2016 2015 Accrued executive severance $ 100,000 $ 100,000 Accrued audit and tax preparation 100,000 93,500 Accrued legal professional fees 45,000 76,500 Deferred rent 41,341 - Accrued outside services 31,533 58,813 Deferred revenue 18,810 - Accrued board of director's fees 16,000 - Accrued clinical study expenses 13,650 22,777 Accrued other 8,754 7,784 $ 375,088 $ 359,374 On November 6, 2012, six six $100,000 four December 31, 2016, first. three four 2014 $300,000 December 31, 2014. December 31, 2016 2015

Note 7 - Notes Payable, Related

Note 7 - Notes Payable, Related Parties	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	7. Notes payable, related parties The notes payable, related parties were issued in conjunction with the Company’s purchase of the orthopedic division of HealthTronics, Inc. on August 1, 2005. 6% June 30, 2010, September 30, 2010. August 1, 2015. On June 28, 2016, second January 31, 2018. On June 15, 2015, January 31, 2017. n connection with the Note Amendment, the Company entered into a security agreement with HealthTronics, Inc. to provide a first The notes payable, related parties bear interest at 8% August 1, 2015 2% 20% The notes payable, related parties had an aggregate outstanding principal balance of $5,364,572, $8,171 December 31, 2016 $5,348,112, $24,631 December 31, 2015, In addition, the Company, in connection with the Note Amendment, issued to HealthTronics, Inc. on June 15, 2015, 3,310,000 $0.001 $0.55 one ten $0.0112 $36,989 In addition, the Company, in connection with the Second Amendment, issued to HealthTronics, Inc. on June 28, 2016, 1,890,000 $0.08 3,310,000 June 15, 2015 $0.08 $0.005 $9,214 Accrued interest currently payable totaled $109,426 $239,803 December 31, 2016 2015, As of January 1, 2017, Maturities on notes payable, related parties are as follows: Years ending December 31, Amount 2017 $ 5,372,742 2018 - Total $ 5,372,742 Interest expense on notes payable, related parties totaled $541,982 $413,200 December 31, 2016 2015,

Note 8 - Short Term Loan

Note 8 - Short Term Loan	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Short-term Debt [Text Block]	8. Short term loan On December 21, 2016, $100,000. March 31, 2017, In addition, the Company will issue to the Holder 500,000 $0.001 $0.17. one March 17, 2019. $0.1168, the Black-Scholes option pricing model, and $58,400

Note 9 - Income Taxes

Note 9 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	9. Income taxes The Company files income tax returns in the United States federal jurisdiction and various state and foreign jurisdictions. The Company is no longer subject to United States federal and state and non-United States income tax examinations by tax authorities for years before 2008. Deferred income taxes are provided for temporary differences between the carrying amounts and tax basis of assets and liabilities. Deferred taxes are classified as current or noncurrent based on the financial statement classification of the related asset or liability giving rise to the temporary difference. For those deferred tax assets or liabilities (such as the tax effect of the net operating loss carryforwards) which do not relate to a financial statement asset or liability, the classification is based on the expected reversal date of the temporary difference. The income tax provision (benefit) from continuing operations consists of the following at December 31, 2016 2015: 2016 2015 Current: Federal $ - $ - State - - Foreign - - - - Deferred: Federal (1,367,488 ) (1,605,319 ) State (150,246 ) (176,377 ) Foreign 7,128 2,419 Change in valuation allowance 1,510,606 1,779,277 $ - $ - The income tax provision (benefit) amounts differ from the amounts computed by applying the United States federal statutory income tax rate of 35% December 31, 2016 2015: 2016 2015 Tax expense (benefit) at statutory rate $ (2,253,664 ) $ (1,683,600 ) Increase (reduction) in income taxes resulting from: State income taxes (benefit), net of federal benefit (160,335 ) (119,778 ) Non-deductible (gain) loss on warrant valuation adjustment 665,719 (19,895 ) Income from foreign subsidiaries 17,077 12,330 Deferred tax true up - 1,803,402 Change in valuation allowance - United States 1,510,606 (24,125 ) Other 220,597 31,666 Income tax expense (benefit) $ - $ - The tax effects of temporary differences that give rise to the deferred tax assets at December 31, 2016 2015 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 27,839,703 $ 26,451,449 Net operating loss carryforwards - foreign 120,451 127,578 Excess of tax basis over book value of property and equipment 13,933 20,158 Excess of tax basis over book value of intangible assets 447,626 443,597 Stock-based compensation 2,038,638 1,834,172 Accrued employee compensation 24,030 90,442 Captialized equity costs 75,471 75,471 Inventory reserve 28,777 35,156 30,588,629 29,078,023 Valuation allowance (30,588,629 ) (29,078,023 ) Net deferred tax assets $ - $ - During 2015, 2015 The Company’s ability to use its net operating loss carryforwards could be limited and subject to annual limitations. In connection with future offerings, the Company may 50% may may The federal net operating loss carryforwards at December 31, 2016 2025.

Note 10 - Equity Transactions

Note 10 - Equity Transactions	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10 . Equity Transactions Warrant Exercise On October 20, 2016, 185,000 185,000 $0.08 On October 14, 2016, 258,333 258,333 $0.08 On September 20, 2016, 400,000 400,000 $0.08 Cashless Warrant Exercise On November 18, 2016, 117,510 143,400 $0.0334 $0.185 On September 8, 2016, 526,288 971,667 $0.06 $0.11 On August 23, 2016, 343,434 971,667 $0.06 $0.17 On August 23, 2016, 1,640,589 4,641,667 $0.06 $0.17 2016 On August 11, 2016, “2016 4(a)(2) 1933, 506 2016 $0.06 one (1) $0.001 one (1) one (1) $0.08 On August 25, 2016 September 27, 2016 2016 22,766,667 5,533,334, $1,366,000 $332,000, The Company, in connection with the 2016 28,300,001 $0.08 one March 17, 2019. Pursuant to the terms of a Registration Rights Agreement that the Company entered with the accredited investors in connection with the 2016 may Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 2016 $75,000. 2016 $60,000. At the closing of the 2016 $169,800 2,830,000 Consulting Agreement In August 2016, 435,392 December 31, 2016. Convertible Debenture and Restricted Stock On July 29, 2016, $200,000, $175,000 10% 4(a)(2) 506 one The Investor is entitled to, at any time or from time to time, commencing on the date that is one fifty one (151) (70%) twenty (20) (65%) twenty (20) The Company recorded $124,900 The Debenture is secured by the accounts receivable of the Company and, unless earlier redeemed, matures on the third $2,500.00) 835,000 $0.06 $50,100 In September 2016, $210,000 105% $10,000 2016 On March 11, 2016, April 6, 2016, April 15, 2016 “2016 25,495,835, 3,083,334 1,437,501, $1,529,750, $185,000, $86,200, 20% June 15, 2015 2016 The Company, in connection with the 2016 30,016,670 $0.08 one March 17, 2019. Pursuant to the terms of a Registration Rights Agreement that the Company entered into with the investors in connection with the 2016 February 16, 2016. Michael N. Nemelka, the brother of a member of the Company’s board of directors and an existing shareholder of the Company, was a purchaser in the 2016 $100,000. 2016 $75,000. At the closing of the 2016 , the Company paid Newport Coast Securities, Inc., the placement agent for the equity offering, cash compensation of $180,095 3,001,667 $4,000 $20,000 Series A Warrant Conversion On January 13, 2016, $0.001 $0.001 The Exchange was based on the following exchange ratio (the “Exchange Ratio”): 1 0.4685 9.99% January 12, 2016 In the Exchange an aggregate number of 23,701,428 7,447,954 293 1 12,500 may In connection with entering into the Exchange Agreement, the Company also entered into a Registration Rights Agreement, dated January 13, 2016, February 16, 2016.

Note 11 - Preferred Stock

Note 11 - Preferred Stock	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Preferred Stock [Text Block]	11. Preferred Stock The Company’s Articles of Incorporation authorize the issuance of up to 5,000,000 may January 12, 2016, 293 $0.001 $1,000 January 13, 2016, 293 10). Under the Certificate of Designation, holders of Series B Convertible Preferred Stock are entitled to receive dividends equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends (other than dividends in the form of common stock) actually paid on shares of the common stock when, as and if such dividends are paid. Such holders will participate on an equal basis per-share with holders of common stock in any distribution upon winding up, dissolution, or liquidation of the Company. Holders of Series B Convertible Preferred Stock are entitled to convert each share of Series A Convertible Preferred Stock into 2,000 9.99% On April 29, 2016, 293 3,657,278 April 29, 2016, no On March 14, 2014, 6,175 $0.001 $1,000 March 17, 2014, 6,175 January 6, 2015 no

Note 12 - Warrants

Note 12 - Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Warrants [Text Block]	1 2. Warrants A summary of warrants as of December 31, 2016 2015, December 31, 2016 2015, Outstanding Outstanding Outstanding as of as of as of December 31, December 31, December 31, Warrant class 2014 Issued Exercised Expired 2015 Issued Exercised Converted Expired 2016 Class E Warrants 3,576,737 - - - 3,576,737 - - - (3,576,737 ) - Class F Warrants 300,000 - - - 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 - - - 629,378 4,012,289 (4,641,667 ) - - - Class K Warrants - 3,310,000 - - 3,310,000 1,890,000 - - - 5,200,000 Class L Warrants - - - - - 66,788,338 (843,333 ) - - 65,945,005 Class M Warrants - - - - - 1,943,333 (1,943,333 ) - - - Series A Warrants 25,951,421 - - - 25,951,421 - (143,400 ) (23,701,427 ) - 2,106,594 Series B Warrants 15,570,852 - - (15,570,852 ) - - - - - - 50,563,538 3,310,000 - (15,570,852 ) 38,302,686 74,633,960 (7,571,733 ) (23,701,427 ) (3,576,737 ) 78,086,749 A summary of the warrant exercise price per share and expiration date is presented as follows: Exercise Expiration price/share date Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class K Warrants $ 0.08 June 2025 Class L Warrants $ 0.08 March 2019 Series A Warrants $ 0.03 February 2021 The exercise price and the number of shares covered by the warrants will be adjusted if the Company has a stock split, if there is a recapitalization of the Company’s common stock, or if the Company consolidates with or merges into another company. The exercise price of the Class K Warrants and the Series A Warrants are subject to a “down-round” anti-dilution adjustment if the Company issues or is deemed to have issued securities at a price lower than the then applicable exercise price of the warrants. The Class K Warrants may may may In February 2013, 2,000,000 $0.35 five 300,000 1,700,000 $5,000,000, June 8, 2013. 1,700,000 The Company recorded the underlying cost of the 300,000 In June 2015, 7), 3,310,000 $0.001 $0.55 one ten In June 2016, 7), 1,890,000 $0.08 3,310,000 June 15, 2015 $0.08 ten The Class J Warrants, the Class K Warrants, the Series A Warrants and the Series B Warrants are derivative financial instruments. The estimated fair value of the Class J Warrants at the date of grant was $12,776. $36,989 $557,733 2014 $47,974 18% 2014, March 2015. The estimated fair values were determined using a binomial option pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect estimated fair value at each period end, with any decrease or increase in the estimated fair value being recorded in other income or expense accordingly, as adjustments to the fair value of derivative liabilities. Various factors are considered in the pricing models the Company uses to value the warrants, including the Company’s current common stock price, the remaining life of the warrants, the volatility of the Company’s common stock price, and the risk-free interest rate. In addition, as of the valuation dates, management assessed the probabilities of future financing and other re-pricing events in the binominal valuation models. A summary of the changes in the warrant liability as of December 31, 2016 December 31, 2015, December 31, 2016 2015, Class J Class K Class M Series A Series B Warrants Warrants Warrants Warrants Warrants Total Warrant liability as of December 31, 2014 $ 3,839 $ - $ - $ 155,709 $ 78 $ 159,626 Issued - 36,990 - - - 36,990 Change in fair value (939 ) (14,290 ) - (43,209 ) (78 ) (58,516 ) Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ - $ 138,100 Issued - 25,350 9,091 - - 34,441 Change in fair value 150,275 835,950 105,401 1,132,092 - 2,223,718 Redeemed (153,175 ) - (114,492 ) (886,472 ) - (1,154,139 ) Warrant liability as of December 31, 2016 $ - $ 884,000 $ - $ 358,120 $ - $ 1,242,120

Note 13 - Commitments and Conti

Note 13 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 3. Commitments and contingencies Operating Leases The Company leases office and storage space. Rent expense for the years ended December 31, 2016 2015, $178,073 $155,926, Year ending December 31, Amount 2017 $ 115,486 2018 135,704 2019 139,775 2020 143,969 2021 148,288 Total $ 683,222 Litigation The Company is involved in various legal matters that have arisen in the ordinary course of business. While the ultimate outcome of these matters is not presently determinable, it is the opinion of management that the resolution will not have a material adverse effect on the financial position or results of operations of the Company.

Note 14 - Stock-based Compensat

Note 14 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	1 4. Stock-based compensation On November 1, 2010, 2006 January 1, 2010 may three ten December 31, 2016 2015 22,500,000 12,500,000 On November 9, 2016, two 2,830,000 $0.18 $0.1524 $431,292. On June 16, 2016, two 3,300,000 $0.04 $0.0335 $110,550. On October 1, 2015, 1,900,000 $0.11 $0.11 $209,000. On October 1, 2015, 1,450,000 $0.50 $0.10 $145,000. On August 13, 2015, Using the Black-Scholes option pricing model, management has determined that the options had a fair value resulting in compensation expense of $98,100. On April 28, 2015, two 50,000 $0.55 2015. $0.11 $11,107. 2015. On May 7, 2014, 900,000 $0.55 $0.48 $429,001 three $6,000 $30,000 December 31, 2016 2015, On February 21, 2013, 2,243,644 $0.35 $0.223 $499,621. $0 $11,327 December 31, 2016 2015, The fair value of each option award is estimated on the date of grant using the Black-Scholes option pricing model using the following weighted average assumptions for the years ended December 31, 2016 2015: 2016 2015 Weighted average expected life in years 5.0 5.0 Weighted average risk free interest rate 1.28 % 1.42 % Weighted average volatility 133.54 % 120.63 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 % The expected life of options granted represent the period of time that options granted are expected to be outstanding and are derived from the contractual terms of the options granted. The risk-free rate for periods within the contractual life of the option is based on the United States Treasury yield curve in effect at the time of the grant. Since there is a limited trading history for our common stock, the expected volatility is based on historical data from companies similar in size and value to us. We estimate pre-vesting forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The expected dividend yield is based on our historical dividend experience, however, since our inception, we have not declared dividends. The amount of stock-based compensation expense recognized during a period is based on the portion of the awards that are ultimately expected to vest. Ultimately, the total expense recognized over the vesting period will equal the fair value of the awards that actually vest. For the years ended December 31, 2016 2015, $547,842 $504,534, A summary of option activity as of December 31, 2016 2015, December 31, 2016 2015, Weighted Average Exercise Price Options per share Outstanding at December 31, 2014 7,206,830 $ 1.31 Granted 4,950,000 $ 0.35 Exercised - $ - Cancelled - $ - Forfeited or expired (2,083,445 ) $ 2.39 Outstanding at December 31, 2015 10,073,385 $ 0.62 Granted 6,130,000 $ 0.10 Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding at December 31, 2016 16,203,385 $ 0.38 Vested and exercisable at December 31, 2016 16,203,385 $ 0.38 The range of exercise prices for options was $0.04 $2.00 December 31, 2016 2015. $702,500 $0 December 31, 2016 2015, $702,500 $0 December 31, 2016 2015, The weighted average remaining contractual term for outstanding exercisable stock options is 5.88 7.46 December 31, 2016 2015, A summary of the Company’s nonvested options as of December 31, 2016 2015, December 31, 2016 2015, Weighted Average Exercise Price Options per share Outstanding at December 31, 2014 914,542 $ 0.37 Granted 4,950,000 $ 0.35 Vested (5,672,874 ) $ 0.36 Cancelled - $ - Forfeited or expired (16,666 ) $ 0.55 Outstanding at December 31, 2015 175,002 $ 0.36 Granted 6,130,000 $ 0.10 Vested (6,305,002 ) $ 0.11 Cancelled - $ - Forfeited or expired - $ - Outstanding at December 31, 2016 - $ -

Note 15 - Segment and Geographi

Note 15 - Segment and Geographic Information	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	15 . Segment and geographic information The Company has one

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	16 . Subsequent events Warrant Exercise On January 24, 2017, 600,000 600,000 $0.08 $48,000. On March 10, 2017, 363,333 363,333 $0.08 $29,067. Cashless Warrant Exercise On January 20, 2017, 15,951 20,000 $0.0334 $0.165 On January 26, 2017, 79,998 100,000 $0.0334 $0.1669 On February 2, 2017, 158,240 100,000 $0.0334 $0.17 On February 6, 2017, 80,804 100,000 $0.0334 $0.174 On March 13, 2017, 297,035 583,333 $0.08 $0.163

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation 830, Foreign Currency Matters
Consolidation, Policy [Policy Text Block]	Principles of consolidation
Use of Estimates, Policy [Policy Text Block]	Estimates may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents 90 may
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk and limited suppliers 50% 32% December 31, 2016, 87% 10% December 31, 2016. 37% 29% December 31, 2015, 63% 10% December 31, 2015. We depend on suppliers for product component materials and other components that are subject to stringent regulatory requirements. We currently purchase most of our product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production. If this were to occur, it may may one may
Receivables, Policy [Policy Text Block]	Accounts receivable 60
Inventory, Policy [Policy Text Block]	Inventory first first The Company analyzes its inventory levels and writes down inventory that has, or is expected to, become obsolete.
Depreciation, Depletion, and Amortization [Policy Text Block]	Depreciation of property and equipment 3 5 15 3 3 2
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible assets 11.4 T he Company regularly reviews intangible assets to determine if facts and circumstances indicate that the useful life is shorter than the Company originally estimated or that the carrying amount of the assets may ● Significant delays or obstacles encountered in the dermaPACE device clinical trial and PMA application; ● Significant changes in the manner in which the Company uses its assets or significant changes in the Company’s overall business strategy; and ● Significant underperformance of the Company’s assets relative to future operating results. If such facts and circumstances exist, the Company assesses the recoverability of the intangible assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives against their respective carrying amounts. If recognition of an impairment charge is necessary, it is measured as the amount by which the carrying amount of the intangible asset exceeds its fair value.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair value of financial instruments The Company has adopted ASC 820 10, Fair Value Measurements The ASC 820 10 one three Level 1 Level 2 1 Level 3 The Company accounts for derivative instruments under ASC 815, Accounting for Derivative Instruments and Hedging Activities 815 3 The following table sets forth a summary of changes in the fair value of the derivative liability for the year ended December 31, 2016: Warrant Liability Balance at December 31, 2015 $ 138,100 New issuances 34,441 Warrant redemption (1,154,139 ) Change in fair value 2,223,718 Balance at December 31, 2016 $ 1,242,120 The Company’s notes payable, related parties had an aggregate outstanding principal balance of $5,364,572, $8,171 December 31, 2016 $5,348,112, $24,631 December 31, 2015, eight June 15, 2015. 3 $4,923,723 $4,844,792 December 31, 2016 2015,
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets may
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling costs
Income Tax, Policy [Policy Text Block]	I ncome taxes 740, Income Taxes . Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided for the deferred tax assets, including loss carryforwards, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. A provision of ASC 740, Income Taxes 48) 740 The Company will recognize in income tax expense interest and penalties related to income tax matters. For the years ended December 31, 2016 2015,
Earnings Per Share, Policy [Policy Text Block]	Loss per share 260, Earnings Per Share 260, To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net income (loss) per share. As a result of the net loss for the years ended December 31, 2016 2015, 94,290,134 48,376,071 December 31, 2016 2015,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive income 220, Comprehensive Income
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-based compensation 718, Compensation – Stock Compensation 718, three
Research and Development Expense, Policy [Policy Text Block]	Research and d evelopment third
New Accounting Pronouncements, Policy [Policy Text Block]	Recent pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09), 2014 09 2014 09 five may December 15, 2017, 2014 09 July 2015, one 2014 09, first 2019 first 2018. August 2015, 2015 14, Revenue from Contracts with Customers (Topic 606) 2014 09 one 2014 09 December 31, 2017, 2014 09 In August 2014, 2014 15, 205 40): December 15, 2016, fourth 2016. In April 2015, 2015 03, Interest-Imputation of Interest (Subtopic 835 30): first December 15, 2015. first 2016. In July 2015, 2015 11, Simplifying the Measurement of Inventory 2015 11), first first 2015 11 first December 15, 2016, 2015 11 January 1, 2016. In November 2015, 2015 17, Income Taxes (Topic 740): Classification of Deferred Taxes December 15, 2016, In February 2016, 2016 02, Leases (Topic 842) December 15, 2018, In March 2016, 2016 09, Compensation – Stock Compensation (Topic 718). December 31, 2016. In August 2016, 2016 15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (Topic 230) eight December 15, 2017.

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Warrant Liability Balance at December 31, 2015 $ 138,100 New issuances 34,441 Warrant redemption (1,154,139 ) Change in fair value 2,223,718 Balance at December 31, 2016 $ 1,242,120

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	2016 2015 Inventory - finished goods $ 218,592 $ 290,623 Inventory - parts 89,621 87,450 Gross inventory 308,213 378,073 Provision for losses and obsolescence (76,260 ) (93,165 ) Net inventory $ 231,953 $ 284,908

Note 4 - Property and Equipme26

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Property, Plant and Equipment [Table Text Block]	2016 2015 Machines and equipment $ 240,295 $ 240,295 Office and computer equipment 156,860 166,398 Devices 82,204 - Software 34,528 34,528 Furniture and fixtures 16,019 20,380 Other assets 2,259 2,259 Total 532,165 463,860 Accumulated depreciation (455,227 ) (459,632 ) Net property and equipment $ 76,938 $ 4,228

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	2016 2015 Patents, at cost $ 3,502,135 $ 3,502,135 Less accumulated amortization (3,502,135 ) (3,195,379 ) Net intangible assets $ - $ 306,756

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	2016 2015 Accrued executive severance $ 100,000 $ 100,000 Accrued audit and tax preparation 100,000 93,500 Accrued legal professional fees 45,000 76,500 Deferred rent 41,341 - Accrued outside services 31,533 58,813 Deferred revenue 18,810 - Accrued board of director's fees 16,000 - Accrued clinical study expenses 13,650 22,777 Accrued other 8,754 7,784 $ 375,088 $ 359,374

Note 7 - Notes Payable, Relat29

Note 7 - Notes Payable, Related Parties (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Years ending December 31, Amount 2017 $ 5,372,742 2018 - Total $ 5,372,742

Note 9 - Income Taxes (Tables)

Note 9 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2016 2015 Current: Federal $ - $ - State - - Foreign - - - - Deferred: Federal (1,367,488 ) (1,605,319 ) State (150,246 ) (176,377 ) Foreign 7,128 2,419 Change in valuation allowance 1,510,606 1,779,277 $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2016 2015 Tax expense (benefit) at statutory rate $ (2,253,664 ) $ (1,683,600 ) Increase (reduction) in income taxes resulting from: State income taxes (benefit), net of federal benefit (160,335 ) (119,778 ) Non-deductible (gain) loss on warrant valuation adjustment 665,719 (19,895 ) Income from foreign subsidiaries 17,077 12,330 Deferred tax true up - 1,803,402 Change in valuation allowance - United States 1,510,606 (24,125 ) Other 220,597 31,666 Income tax expense (benefit) $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2016 2015 Deferred tax assets: Net operating loss carryforwards $ 27,839,703 $ 26,451,449 Net operating loss carryforwards - foreign 120,451 127,578 Excess of tax basis over book value of property and equipment 13,933 20,158 Excess of tax basis over book value of intangible assets 447,626 443,597 Stock-based compensation 2,038,638 1,834,172 Accrued employee compensation 24,030 90,442 Captialized equity costs 75,471 75,471 Inventory reserve 28,777 35,156 30,588,629 29,078,023 Valuation allowance (30,588,629 ) (29,078,023 ) Net deferred tax assets $ - $ -

Note 12 - Warrants (Tables)

Note 12 - Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Outstanding Outstanding as of as of as of December 31, December 31, December 31, Warrant class 2014 Issued Exercised Expired 2015 Issued Exercised Converted Expired 2016 Class E Warrants 3,576,737 - - - 3,576,737 - - - (3,576,737 ) - Class F Warrants 300,000 - - - 300,000 - - - - 300,000 Class G Warrants 1,503,409 - - - 1,503,409 - - - - 1,503,409 Class H Warrants 1,988,095 - - - 1,988,095 - - - - 1,988,095 Class I Warrants 1,043,646 - - - 1,043,646 - - - - 1,043,646 Class J Warrants 629,378 - - - 629,378 4,012,289 (4,641,667 ) - - - Class K Warrants - 3,310,000 - - 3,310,000 1,890,000 - - - 5,200,000 Class L Warrants - - - - - 66,788,338 (843,333 ) - - 65,945,005 Class M Warrants - - - - - 1,943,333 (1,943,333 ) - - - Series A Warrants 25,951,421 - - - 25,951,421 - (143,400 ) (23,701,427 ) - 2,106,594 Series B Warrants 15,570,852 - - (15,570,852 ) - - - - - - 50,563,538 3,310,000 - (15,570,852 ) 38,302,686 74,633,960 (7,571,733 ) (23,701,427 ) (3,576,737 ) 78,086,749
Schedule Of Warrant Exercise Price And Expiration Date [Table Text Block]	Exercise Expiration price/share date Class F Warrants $ 0.35 February 2018 Class G Warrants $ 0.80 July 2018 Class H Warrants $ 0.80 July 2018 Class I Warrants $ 0.85 September 2018 Class K Warrants $ 0.08 June 2025 Class L Warrants $ 0.08 March 2019 Series A Warrants $ 0.03 February 2021
Schedule of Changes in Warrant Liabilities [Table Text Block]	Class J Class K Class M Series A Series B Warrants Warrants Warrants Warrants Warrants Total Warrant liability as of December 31, 2014 $ 3,839 $ - $ - $ 155,709 $ 78 $ 159,626 Issued - 36,990 - - - 36,990 Change in fair value (939 ) (14,290 ) - (43,209 ) (78 ) (58,516 ) Warrant liability as of December 31, 2015 $ 2,900 $ 22,700 $ - $ 112,500 $ - $ 138,100 Issued - 25,350 9,091 - - 34,441 Change in fair value 150,275 835,950 105,401 1,132,092 - 2,223,718 Redeemed (153,175 ) - (114,492 ) (886,472 ) - (1,154,139 ) Warrant liability as of December 31, 2016 $ - $ 884,000 $ - $ 358,120 $ - $ 1,242,120

Note 13 - Commitments and Con32

Note 13 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year ending December 31, Amount 2017 $ 115,486 2018 135,704 2019 139,775 2020 143,969 2021 148,288 Total $ 683,222

Note 14 - Stock-based Compens33

Note 14 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2016 2015 Weighted average expected life in years 5.0 5.0 Weighted average risk free interest rate 1.28 % 1.42 % Weighted average volatility 133.54 % 120.63 % Forfeiture rate 0.0 % 0.0 % Expected dividend yield 0.0 % 0.0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Average Exercise Price Options per share Outstanding at December 31, 2014 7,206,830 $ 1.31 Granted 4,950,000 $ 0.35 Exercised - $ - Cancelled - $ - Forfeited or expired (2,083,445 ) $ 2.39 Outstanding at December 31, 2015 10,073,385 $ 0.62 Granted 6,130,000 $ 0.10 Exercised - $ - Cancelled - $ - Forfeited or expired - $ - Outstanding at December 31, 2016 16,203,385 $ 0.38 Vested and exercisable at December 31, 2016 16,203,385 $ 0.38
Schedule of Other Share-based Compensation, Activity [Table Text Block]	Weighted Average Exercise Price Options per share Outstanding at December 31, 2014 914,542 $ 0.37 Granted 4,950,000 $ 0.35 Vested (5,672,874 ) $ 0.36 Cancelled - $ - Forfeited or expired (16,666 ) $ 0.55 Outstanding at December 31, 2015 175,002 $ 0.36 Granted 6,130,000 $ 0.10 Vested (6,305,002 ) $ 0.11 Cancelled - $ - Forfeited or expired - $ - Outstanding at December 31, 2016 - $ -

Note 1 - Going Concern (Details

Note 1 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss) Attributable to Parent	$ (6,439,040)	$ (4,810,285)
Net Cash Provided by (Used in) Operating Activities	(3,199,453)	(3,473,456)
Working Capital	(7,002,324)
Stockholders' Equity Attributable to Parent	(6,911,600)	(5,877,836)	$ (1,551,400)
Cash and Cash Equivalents, at Carrying Value	$ 133,571	$ 152,930	$ 3,547,071

Note 2 - Summary of Significa35

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Embedded Derivative, Loss on Embedded Derivative	$ 8,171	$ 24,631
Notes Payable, Related Parties		5,348,112
Related Party Transaction, Rate	8.00%
Notes Payable, Fair Value Disclosure	$ 4,923,723	$ 4,844,792
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	94,290,134	48,376,071
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	11 years 146 days
Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Old or Used Devices [Member]
Property, Plant and Equipment, Useful Life	5 years
New Devices [Member]
Property, Plant and Equipment, Useful Life	15 years
Office Equipment [Member]
Property, Plant and Equipment, Useful Life	3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life	3 years
Software and Software Development Costs [Member]
Property, Plant and Equipment, Useful Life	2 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk, Percentage	50.00%	37.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Customer Two [Member]
Concentration Risk, Percentage	32.00%	29.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage	87.00%	63.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage	10.00%	10.00%

Note 2 - Summary of Significa36

Note 2 - Summary of Significant Accounting Policies - Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Balance	$ 138,100
New issuances	34,441
Warrant redemption	(1,154,139)
Change in fair value	2,223,718	$ (58,515)
Balance	$ 1,242,120	$ 138,100

Note 3 - Inventory - Inventory

Note 3 - Inventory - Inventory Components (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory - finished goods	$ 218,592	$ 290,623
Inventory - parts	89,621	87,450
Gross inventory	308,213	378,073
Provision for losses and obsolescence	(76,260)	(93,165)
Net inventory	$ 231,953	$ 284,908

Note 4 - Property and Equipme38

Note 4 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Depreciation	$ 19,858	$ 3,612

Note 4 - Property and Equipme39

Note 4 - Property and Equipment - Components of Property and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, plant and equipment, gross	$ 532,165	$ 463,860
Accumulated depreciation	(455,227)	(459,632)
Net property and equipment	76,938	4,228
Machinery and Equipment [Member]
Property, plant and equipment, gross	240,295	240,295
Office Equipment [Member]
Property, plant and equipment, gross	156,860	166,398
Devices [Member]
Property, plant and equipment, gross	82,204
Software and Software Development Costs [Member]
Property, plant and equipment, gross	34,528	34,528
Furniture and Fixtures [Member]
Property, plant and equipment, gross	16,019	20,380
Other Capitalized Property Plant and Equipment [Member]
Property, plant and equipment, gross	$ 2,259	$ 2,259

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Amortization of Intangible Assets	$ 306,756	$ 306,757

Note 5 - Intangible Assets - Su

Note 5 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Patents, at cost	$ 3,502,135	$ 3,502,135
Less accumulated amortization	(3,502,135)	(3,195,379)
Net intangible assets		$ 306,756

Note 6 - Accrued Expenses (Deta

Note 6 - Accrued Expenses (Details Textual) - USD ($)	Nov. 06, 2012	Dec. 31, 2014
Payments of Accrued Executive Severance Costs		$ 300,000
President [Member]
Bonus Payment Amount to Be Paid Upon Each of Four Bonus Payment Events	$ 100,000

Note 6 - Accrued Expenses - Sum

Note 6 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accrued executive severance	$ 100,000	$ 100,000
Accrued audit and tax preparation	100,000	93,500
Accrued legal professional fees	45,000	76,500
Deferred rent	41,341
Accrued outside services	31,533	58,813
Deferred revenue	18,810
Accrued board of director's fees	16,000
Accrued clinical study expenses	13,650	22,777
Accrued other	8,754	7,784
	$ 375,088	$ 359,374

Note 7 - Notes Payable, Relat44

Note 7 - Notes Payable, Related Parties (Details Textual) - USD ($)	Jun. 28, 2016	Jun. 15, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 21, 2016	Jan. 13, 2016
Related Party Transaction, Rate					8.00%
Notes Payable, Related Parties, Noncurrent						$ 5,348,112
Class of Warrant or Right, Issued During Period					74,633,960	3,310,000
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001	$ 0.001	$ 0.001
Class K Warrants [Member]
Class of Warrant or Right, Issued During Period					1,890,000	3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.08
Health Tronics, Inc [Member]
Related Party Transaction, Rate					6.00%
Notes Payable, Related Parties, Noncurrent					$ 5,364,572	$ 5,348,112
Debt Instrument, Unamortized Discount					8,171	24,631
Common Stock, Par or Stated Value Per Share		$ 0.001
Interest Payable, Current					109,426	239,803
Interest Expense, Related Party					$ 541,982	$ 413,200
Health Tronics, Inc [Member] | Class K Warrants [Member]
Class of Warrant or Right, Issued During Period	1,890,000	3,310,000	1,890,000	3,310,000
Common Stock, Par or Stated Value Per Share				$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08	$ 0.55	$ 0.08	$ 0.55
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1		1
Class of Warrant or Right, Expiration Period		10 years	10 years	10 years
Class of Warrant or Right, Fair Value at Issuance	$ 0.005	$ 0.0112
Class of Warrant or Right, Fair Value Recorded as Debt Discount	$ 9,214	$ 36,989
Health Tronics, Inc [Member] | Note Amendment [Member]
Related Party Transaction, Rate		8.00%
Interest Rate Increase Per Annum		2.00%
Related Party, Notes Payable Manditory Prepayment Rate		20.00%

Note 7 - Notes Payable, Relat45

Note 7 - Notes Payable, Related Parties - Maturities on Notes Payable, Related Parties (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Total		$ 5,348,112
Health Tronics, Inc [Member]
2,017	$ 5,372,742
2,018
Total	$ 5,372,742

Note 8 - Short Term Loan (Detai

Note 8 - Short Term Loan (Details Textual) - USD ($)	Dec. 31, 2016	Dec. 21, 2016	Jan. 13, 2016	Dec. 31, 2015
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001	$ 0.001	$ 0.001
Millennium Park Capital LLC [Member] | Warrants in Connection with Short-term Loan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.17
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Fair Value at Issuance		$ 0.1168
Class of Warrant or Right, Fair Value Recorded as Debt Discount		$ 58,400
Loans Payable [Member] | Millennium Park Capital LLC [Member]
Debt Instrument, Face Amount		$ 100,000

Note 9 - Income Taxes (Details

Note 9 - Income Taxes (Details Textual)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	35.00%

Note 9 - Income Taxes - Income

Note 9 - Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal
State
Foreign
Deferred:
Federal	(1,367,488)	(1,605,319)
State	(150,246)	(176,377)
Foreign	7,128	2,419
Change in valuation allowance	$ 1,510,606	$ 1,779,277

Note 9 - Income Taxes - Reconci

Note 9 - Income Taxes - Reconciliation of Income Tax Provision (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Tax expense (benefit) at statutory rate	$ (2,253,664)	$ (1,683,600)
Increase (reduction) in income taxes resulting from:
State income taxes (benefit), net of federal benefit	(160,335)	(119,778)
Income from foreign subsidiaries	17,077	12,330
Deferred tax true up		1,803,402
Change in valuation allowance - United States	1,510,606	(24,125)
Other	220,597	31,666
Income tax expense (benefit)
Warrant [Member]
Increase (reduction) in income taxes resulting from:
Non-deductible (gain) loss on warrant valuation adjustment	$ 665,719	$ (19,895)

Note 9 - Income Taxes - Deferre

Note 9 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 27,839,703	$ 26,451,449
Net operating loss carryforwards - foreign	120,451	127,578
Excess of tax basis over book value of property and equipment	13,933	20,158
Excess of tax basis over book value of intangible assets	447,626	443,597
Stock-based compensation	2,038,638	1,834,172
Accrued employee compensation	24,030	90,442
Captialized equity costs	75,471	75,471
Inventory reserve	28,777	35,156
	30,588,629	29,078,023
Valuation allowance	(30,588,629)	(29,078,023)
Net deferred tax assets	$ 0	$ 0

Note 10 - Equity Transactions (

Note 10 - Equity Transactions (Details Textual)	Nov. 18, 2016$ / sharesshares	Oct. 20, 2016$ / sharesshares	Oct. 14, 2016$ / sharesshares	Sep. 27, 2016USD ($)shares	Sep. 20, 2016$ / sharesshares	Sep. 08, 2016$ / sharesshares	Aug. 25, 2016USD ($)shares	Aug. 23, 2016$ / sharesshares	Aug. 11, 2016USD ($)$ / shares$ / itemshares	Jul. 29, 2016USD ($)shares	Apr. 15, 2016USD ($)shares	Apr. 06, 2016USD ($)shares	Mar. 11, 2016USD ($)$ / sharesshares	Jan. 13, 2016$ / sharesshares	Sep. 30, 2016USD ($)	Aug. 31, 2016shares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 21, 2016$ / shares	Jun. 15, 2015$ / shares
Class of Warrant or Right, Exercised During Period																	7,571,733
Common Stock, Par or Stated Value Per Share | $ / shares														$ 0.001			$ 0.001	$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues | $																	$ 1,596,855
Class of Warrant or Right, Issued During Period																	74,633,960	3,310,000
Proceeds from Issuance of Private Placement | $																	$ 1,528,200
Stock Issued During Period, Shares, Issued for Services																435,392
Proceeds from Issuance or Sale of Equity | $																	1,596,855
Preferred Stock, Par or Stated Value Per Share | $ / shares														$ 0.001
Convertible Debentures [Member]
Debt Instrument, Face Amount | $										$ 200,000
Proceeds from Convertible Debt | $										$ 175,000							175,000
Original Issue Discount, Percentage										10.00%
Conversion Rate as Percentage of Lowest Closing Bid Price if Company if DWAC Operational										70.00%
Conversion Rate as Percentage of Lowest Closing Bid Price if Company is Not DWAC Operational										65.00%
Debt Instrument, Convertible, Beneficial Conversion Feature, Interest Expense | $										$ 124,900
Debt Instrument, Fee Amount | $										$ 835,000
Debt Instrument, Shares, Commitment Fee										0.06
Interest Expense, Debt | $										$ 50,100
Repayments of Convertible Debt | $															$ 210,000		$ 210,000
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed															105.00%
Redemption Premium, Interest Expense | $															$ 10,000
Health Tronics, Inc [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																				$ 0.001
Common Stock [Member]
Stock Issued During Period, Shares, New Issues																	30,016,670
Stock Issued During Period, Value, New Issues | $																	$ 30,017
Stock Issued During Period, Shares, Issued for Services																	435,392
2016 Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 0.08
Purchase Price of Unit | $ / item									0.06
Common Stock Per Unit									1
Common Stock, Par or Stated Value Per Share | $ / shares									$ 0.001
Warrant Per Unit									1
Stock Issued During Period, Shares, New Issues				5,533,334			22,766,667
Stock Issued During Period, Value, New Issues | $				$ 332,000			$ 1,366,000
2016 Private Placement [Member] | Michael N. Nemelka [Member]
Proceeds from Issuance of Private Placement | $									$ 75,000
2016 Private Placement [Member] | Michael Stolarski [Member]
Proceeds from Issuance of Private Placement | $									$ 60,000
2016 Private Placement [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
The 2016 Equity Offering [Member]
Stock Issued During Period, Shares, New Issues											1,437,501	3,083,334	25,495,835
Proceeds from Issuance of Private Placement Gross | $											$ 86,200	$ 185,000	$ 1,529,750
The 2016 Equity Offering [Member] | Escrow Fee [Member]
Payments of Stock Issuance Costs | $											4,000
The 2016 Equity Offering [Member] | Attorney Fee [Member]
Payments of Stock Issuance Costs | $											20,000
The 2016 Equity Offering [Member] | Michael N. Nemelka [Member]
Proceeds from Issuance or Sale of Equity | $													100,000
The 2016 Equity Offering [Member] | Michael Stolarski [Member]
Proceeds from Issuance or Sale of Equity | $													$ 75,000
The 2016 Equity Offering [Member] | Health Tronics, Inc [Member]
Related Party, Notes Payable Manditory Prepayment Rate													20.00%
West Park Capital, Inc [Member] | 2016 Private Placement [Member]
Payments of Stock Issuance Costs | $									$ 169,800
Newport Coast Securities, Inc. [Member] | The 2016 Equity Offering [Member] | Placement Agent Fee [Member]
Payments of Stock Issuance Costs | $											$ 180,095
Class L Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised		185,000	258,333		400,000
Class of Warrant or Right, Exercised During Period		185,000	258,333		400,000												843,333
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 0.08	$ 0.08		$ 0.08												$ 0.08
Class of Warrant or Right, Issued During Period																	66,788,338
Class L Warrants [Member] | 2016 Private Placement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 0.08
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right									1
Class of Warrant or Right, Issued During Period									28,300,001
Class L Warrants [Member] | The 2016 Equity Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares													$ 0.08
Class of Warrant or Right, Issued During Period													30,016,670
Class L Warrants [Member] | The 2016 Equity Offering [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right													1
Class L Warrants [Member] | West Park Capital, Inc [Member] | 2016 Private Placement [Member]
Class of Warrant or Right, Issued During Period									2,830,000
Class L Warrants [Member] | Newport Coast Securities, Inc. [Member] | The 2016 Equity Offering [Member]
Class of Warrant or Right, Issued During Period											3,001,667
Series A Warrants [Member]
Class of Warrant or Right, Exercised During Period																	143,400
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																	$ 0.03
Class of Warrant or Right, Issued During Period
Class of Warrant or Right, Exchange Ratio														0.4685
Common Stock, Ownership Threshold														9.99%
Series A Warrants [Member] | Convertible Common Stock [Member]
Stock Issued During Period, Shares, New Issues														7,447,954
Warrants Converted During Period														23,701,428
Convertible Preferred Stock, Shares Issued upon Conversion														12,500
Series A Warrants [Member] | Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues														293
Series A Warrants [Member] | DeMint Law, PLLC [Member]
Stock Issued During Period, Shares, Warrants Exercised	117,510
Class of Warrant or Right, Exercised During Period	143,400
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.0334
Share Price | $ / shares	$ 0.185
Class M Warrants [Member]
Class of Warrant or Right, Exercised During Period																	1,943,333
Class of Warrant or Right, Issued During Period																	1,943,333
Class M Warrants [Member] | Vigere Capital LP [Member]
Stock Issued During Period, Shares, Warrants Exercised						526,288
Class of Warrant or Right, Exercised During Period						971,667
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 0.06
Share Price | $ / shares						$ 0.11
Class M Warrants [Member] | JDF Capital, Inc. [Member]
Stock Issued During Period, Shares, Warrants Exercised								343,434
Class of Warrant or Right, Exercised During Period								971,667
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 0.06
Share Price | $ / shares								$ 0.17
Class J Warrants [Member]
Class of Warrant or Right, Exercised During Period																	4,641,667
Class of Warrant or Right, Issued During Period																	4,012,289
Class J Warrants [Member] | JDF Capital, Inc. [Member]
Stock Issued During Period, Shares, Warrants Exercised								1,640,589
Class of Warrant or Right, Exercised During Period								4,641,667
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares								$ 0.06
Share Price | $ / shares								$ 0.17

Note 11 - Preferred Stock (Deta

Note 11 - Preferred Stock (Details Textual) - USD ($)	Apr. 29, 2016	Jan. 13, 2016	Mar. 17, 2014	Dec. 31, 2016	Jan. 12, 2016	Dec. 31, 2015	Jan. 06, 2015	Mar. 14, 2014
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Undesignated Preferred Stock [Member]
Preferred Stock, Shares Authorized				4,993,532		4,993,532
Preferred Stock, Par or Stated Value Per Share				$ 0.001		$ 0.001
Preferred Stock, Shares Outstanding				0		0
Undesignated Preferred Stock [Member] | Maximum [Member]
Preferred Stock, Shares Authorized				5,000,000
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized				293	293	293
Preferred Stock, Par or Stated Value Per Share				$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Stated Value Per Share					$ 1,000
Stock Issued During Period, Shares, New Issues		293
Convertible Preferred Stock, Shares Issued upon Conversion		2,000
Beneficial Ownership Limitation, Percentage of Common Stock Shares Outstanding		9.99%
Conversion of Stock, Shares Converted	293
Preferred Stock, Shares Outstanding	0			0		0
Common Stock [Member]
Conversion of Stock, Shares Issued	3,657,278
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized								6,175
Preferred Stock, Par or Stated Value Per Share								$ 0.001
Preferred Stock, Stated Value Per Share								$ 1,000
Stock Issued During Period, Shares, New Issues			6,175
Preferred Stock, Shares Outstanding							0

Note 12 - Warrants (Details Tex

Note 12 - Warrants (Details Textual) - USD ($)	Jun. 28, 2016	Jun. 15, 2015	Jun. 30, 2016	Jun. 30, 2015	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 21, 2016	Jan. 13, 2016	Dec. 31, 2014	Mar. 17, 2014	Feb. 10, 2014
Class of Warrant or Right, Issued During Period							74,633,960	3,310,000
Class of Warrant or Right, Expired During Period							3,576,737	15,570,852
Class of Warrant or Right, Outstanding							78,086,749	38,302,686			50,563,538
Common Stock, Par or Stated Value Per Share							$ 0.001	$ 0.001	$ 0.001	$ 0.001
Warrants and Rights Outstanding								$ 138,100			$ 159,626
18% Convertible Promissory Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage													18.00%
Health Tronics, Inc [Member]
Common Stock, Par or Stated Value Per Share		$ 0.001
Class F Warrants [Member]
Class of Warrant or Right, Issued During Period					2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.35		$ 0.35
Warrants Term					5 years
Warrants Converted During Period					300,000
Warrants Vesting Contingent Upon Captial Raise Completion					1,700,000
Capital Raise Threshold For Vesting Of Warrants					$ 5,000,000
Class of Warrant or Right, Expired During Period						1,700,000
Class of Warrant or Right, Outstanding							300,000	300,000			300,000
Class K Warrants [Member]
Class of Warrant or Right, Issued During Period							1,890,000	3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.08
Class of Warrant or Right, Expired During Period
Class of Warrant or Right, Outstanding							5,200,000	3,310,000
Warrants and Rights Outstanding		$ 36,989						$ 22,700
Class K Warrants [Member] | Health Tronics, Inc [Member]
Class of Warrant or Right, Issued During Period	1,890,000	3,310,000	1,890,000	3,310,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08	$ 0.55	$ 0.08	$ 0.55
Common Stock, Par or Stated Value Per Share				$ 0.001
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1		1
Class of Warrant or Right, Expiration Period		10 years	10 years	10 years
Class J Warrants [Member]
Class of Warrant or Right, Issued During Period							4,012,289
Class of Warrant or Right, Expired During Period
Class of Warrant or Right, Outstanding								629,378			629,378
Warrants and Rights Outstanding								$ 2,900			$ 3,839		$ 12,776
Series A and B Warrants [Member] | 18% Convertible Promissory Notes [Member]
Warrants and Rights Outstanding													$ 47,974
Series A and B Warrants [Member] | Private Placement [Member]
Warrants and Rights Outstanding												$ 557,733

Note 12 - Warrants - Warrant Ac

Note 12 - Warrants - Warrant Activity (Details) - shares	Oct. 20, 2016	Oct. 14, 2016	Sep. 20, 2016	Feb. 28, 2013	Dec. 31, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right, Outstanding						78,086,749	38,302,686	50,563,538
Class of Warrant or Right, Issued During Period						74,633,960	3,310,000
Warrants Exercised (in shares)						(7,571,733)
Warrants Converted (in shares)						(3,576,737)	(15,570,852)
Warrants Expired (in shares)						78,086,749	38,302,686
Warrants Outstanding (in shares)						(23,701,427)
Class E Warrants [Member]
Class of Warrant or Right, Outstanding							3,576,737	3,576,737
Class of Warrant or Right, Issued During Period						0
Warrants Exercised (in shares)
Warrants Converted (in shares)						(3,576,737)
Warrants Expired (in shares)							3,576,737
Warrants Outstanding (in shares)
Class F Warrants [Member]
Class of Warrant or Right, Outstanding						300,000	300,000	300,000
Class of Warrant or Right, Issued During Period				2,000,000
Warrants Exercised (in shares)
Warrants Converted (in shares)					(1,700,000)
Warrants Expired (in shares)						300,000	300,000
Warrants Outstanding (in shares)
Class G Warrants [Member]
Class of Warrant or Right, Outstanding						1,503,409	1,503,409	1,503,409
Class of Warrant or Right, Issued During Period
Warrants Exercised (in shares)
Warrants Converted (in shares)
Warrants Expired (in shares)						1,503,409	1,503,409
Warrants Outstanding (in shares)
Class H Warrants [Member]
Class of Warrant or Right, Outstanding						1,988,095	1,988,095	1,988,095
Class of Warrant or Right, Issued During Period
Warrants Exercised (in shares)
Warrants Converted (in shares)
Warrants Expired (in shares)						1,988,095	1,988,095
Warrants Outstanding (in shares)
Class I Warrants [Member]
Class of Warrant or Right, Outstanding						1,043,646	1,043,646	1,043,646
Class of Warrant or Right, Issued During Period
Warrants Exercised (in shares)
Warrants Converted (in shares)
Warrants Expired (in shares)						1,043,646	1,043,646
Warrants Outstanding (in shares)
Class J Warrants [Member]
Class of Warrant or Right, Outstanding							629,378	629,378
Class of Warrant or Right, Issued During Period						4,012,289
Warrants Exercised (in shares)						(4,641,667)
Warrants Converted (in shares)
Warrants Expired (in shares)							629,378
Warrants Outstanding (in shares)
Class K Warrants [Member]
Class of Warrant or Right, Outstanding						5,200,000	3,310,000
Class of Warrant or Right, Issued During Period						1,890,000	3,310,000
Warrants Exercised (in shares)
Warrants Converted (in shares)
Warrants Expired (in shares)						5,200,000	3,310,000
Warrants Outstanding (in shares)
Class L Warrants [Member]
Class of Warrant or Right, Outstanding						65,945,005
Class of Warrant or Right, Issued During Period						66,788,338
Warrants Exercised (in shares)	(185,000)	(258,333)	(400,000)			(843,333)
Warrants Converted (in shares)
Warrants Expired (in shares)						65,945,005
Warrants Outstanding (in shares)
Class M Warrants [Member]
Class of Warrant or Right, Outstanding
Class of Warrant or Right, Issued During Period						1,943,333
Warrants Exercised (in shares)						(1,943,333)
Warrants Converted (in shares)
Warrants Expired (in shares)
Warrants Outstanding (in shares)
Series A Warrants [Member]
Class of Warrant or Right, Outstanding						2,106,594	25,951,421	25,951,421
Class of Warrant or Right, Issued During Period
Warrants Exercised (in shares)						(143,400)
Warrants Converted (in shares)
Warrants Expired (in shares)						2,106,594	25,951,421
Warrants Outstanding (in shares)						(23,701,427)
Series B Warrants [Member]
Class of Warrant or Right, Outstanding								15,570,852
Class of Warrant or Right, Issued During Period
Warrants Exercised (in shares)
Warrants Converted (in shares)							(15,570,852)
Warrants Expired (in shares)
Warrants Outstanding (in shares)

Note 12 - Warrants - Warrant Ex

Note 12 - Warrants - Warrant Exercise Price Per Share and Expiration Date (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Oct. 20, 2016	Oct. 14, 2016	Sep. 20, 2016	Feb. 28, 2013
Class F Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.35				$ 0.35
Expiration date	February 2,018
Class G Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class H Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.80
Expiration date	July 2,018
Class I Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.85
Expiration date	September 2,018
Class K Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Expiration date	June 2,025
Class L Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08	$ 0.08	$ 0.08	$ 0.08
Expiration date	March 2,019
Series A Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.03
Expiration date	February 2,021

Note 12 - Warrants - Changes in

Note 12 - Warrants - Changes in the Warrant Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Warrant liability	$ 138,100	$ 159,626
Issued	34,441	36,990
Change in fair value	2,223,718	(58,516)
Warrant liability		138,100
Redeemed	(1,154,139)
Warrant liability as of December 31, 2016	1,242,120
Class J Warrants [Member]
Warrant liability	2,900	3,839
Issued
Change in fair value	150,275	(939)
Warrant liability		2,900
Redeemed	(153,175)
Warrant liability as of December 31, 2016
Class K Warrants [Member]
Warrant liability	22,700
Issued	25,350	36,990
Change in fair value	835,950	(14,290)
Warrant liability		22,700
Redeemed
Warrant liability as of December 31, 2016	884,000
Class M Warrants [Member]
Warrant liability
Issued	9,091
Change in fair value	105,401
Warrant liability
Redeemed	(114,492)
Warrant liability as of December 31, 2016
Series A Warrants [Member]
Warrant liability	112,500	155,709
Issued
Change in fair value	1,132,092	(43,209)
Warrant liability		112,500
Redeemed	(886,472)
Warrant liability as of December 31, 2016	358,120
Series B Warrants [Member]
Warrant liability		78
Issued
Change in fair value		(78)
Warrant liability
Redeemed
Warrant liability as of December 31, 2016

Note 13 - Commitments and Con57

Note 13 - Commitments and Contingencies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Rent Expense, Net	$ 178,073	$ 155,926

Note 13 - Commitments and Con58

Note 13 - Commitments and Contingencies - Minimum Future Lease Payments Under Operating Lease (Details)	Dec. 31, 2016USD ($)
2,017	$ 115,486
2,018	135,704
2,019	139,775
2,020	143,969
2,021	148,288
Total	$ 683,222

Note 14 - Stock-based Compens59

Note 14 - Stock-based Compensation (Details Textual) - USD ($)	Nov. 09, 2016	Jun. 16, 2016	Oct. 01, 2015	Aug. 13, 2015	Apr. 28, 2015	May 07, 2014	Feb. 21, 2013	Nov. 01, 2010	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period									3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									6,130,000	4,950,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price									$ 0.10	$ 0.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term									5 years 321 days
Employee Stock Option [Member]
Allocated Share-based Compensation Expense									$ 547,842	$ 504,534
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized									22,500,000	12,500,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit									$ 0.04	$ 0.04
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit									$ 2	$ 2
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value									$ 702,500	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value									702,500	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term										7 years 167 days
Stock Incentive Plan [Member] | Active Employees, Members of the Board of Directors, and Members of the Medical Advisory Board [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	2,830,000	3,300,000	1,450,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.18	$ 0.04	$ 0.50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.1524	$ 0.0335	$ 0.10
Allocated Share-based Compensation Expense	$ 431,292	$ 110,550	$ 145,000
Stock Incentive Plan [Member] | Active Employees and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,900,000				2,243,644
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 0.11				$ 0.35
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 0.11				$ 0.223
Allocated Share-based Compensation Expense			$ 209,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options							$ 499,621
Stock Incentive Plan [Member] | Former CEO [Member]
Allocated Share-based Compensation Expense				$ 98,100
Stock Incentive Plan [Member] | Medical Advisory Board Member 1 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value					$ 0.11
Allocated Share-based Compensation Expense					$ 11,107
Stock Incentive Plan [Member] | Active Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						900,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 0.55
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value						$ 0.48
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options						$ 429,001
Stock Incentive Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								10 years
Stock Incentive Plan [Member] | Employee Stock Option [Member] | Active Employees and Directors [Member]
Allocated Share-based Compensation Expense									0	$ 11,327
Stock Incentive Plan [Member] | Employee Stock Option [Member] | Active Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						3 years
Allocated Share-based Compensation Expense									$ 6,000	$ 30,000

Note 14 - Stock-based Compens60

Note 14 - Stock-based Compensation - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Weighted average expected life in years (Year)	5 years	5 years
Weighted average risk free interest rate	1.28%	1.42%
Weighted average volatility	133.54%	120.63%
Forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note 14 - Stock-based Compens61

Note 14 - Stock-based Compensation - Summary of Options Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding, number (in shares)	10,073,385	7,206,830
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.62	$ 1.31
Granted, number (in shares)	6,130,000	4,950,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.10	$ 0.35
Forfeited or expired, number (in shares)		(2,083,445)
Forfeited or expired, weighted average exercise price per share		$ 2.39
Outstanding, number (in shares)	16,203,385	10,073,385
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.38	$ 0.62
Vested and exercisable at December 31, 2016 (in shares)	16,203,385
Vested and exercisable at December 31, 2016 (in dollars per share)	$ 0.38

Note 14 - Stock-based Compens62

Note 14 - Stock-based Compensation - Nonvested Options Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding, number (in shares)	175,002	914,542
Outstanding, weighted average exercise price per share (in dollars per share)	$ 0.36	$ 0.37
Granted, number (in shares)	6,130,000	4,950,000
Granted, weighted average exercise price per share (in dollars per share)	$ 0.10	$ 0.35
Vested, number (in shares)	(6,305,002)	(5,672,874)
Vested, weighted average exercise price per share (in dollars per share)	$ 0.11	$ 0.36
Forfeited or expired (in shares)		(16,666)
Forfeited or expired (in dollars per share)		$ 0.55
Outstanding, number (in shares)		175,002
Outstanding, weighted average exercise price per share (in dollars per share)		$ 0.36

Note 15 - Segment and Geograp63

Note 15 - Segment and Geographic Information (Details Textual)	12 Months Ended
	Dec. 31, 2016
Number of Operating Segments	1

Note 16 - Subsequent Events (De

Note 16 - Subsequent Events (Details Textual) - USD ($)	Mar. 13, 2017	Mar. 10, 2017	Feb. 06, 2017	Feb. 02, 2017	Jan. 26, 2017	Jan. 24, 2017	Jan. 20, 2017	Oct. 20, 2016	Oct. 14, 2016	Sep. 20, 2016	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right, Exercised During Period											7,571,733
Proceeds from Warrant Exercises											$ 67,466
Subsequent Event [Member]
Share Price	$ 0.163		$ 0.174	$ 0.17	$ 0.1669		$ 0.165
Class L Warrants [Member]
Stock Issued During Period, Shares, Warrants Exercised								185,000	258,333	400,000
Class of Warrant or Right, Exercised During Period								185,000	258,333	400,000	843,333
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 0.08	$ 0.08	$ 0.08	$ 0.08
Class L Warrants [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Warrants Exercised		363,333				600,000
Class of Warrant or Right, Exercised During Period		363,333				600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.08				$ 0.08
Proceeds from Warrant Exercises		$ 29,067				$ 48,000
Class L Warrants [Member] | Subsequent Event [Member] | Lucas Hoppel [Member]
Stock Issued During Period, Shares, Warrants Exercised	297,035
Class of Warrant or Right, Exercised During Period	583,333
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.08
Series A Warrants [Member]
Class of Warrant or Right, Exercised During Period											143,400
Class of Warrant or Right, Exercise Price of Warrants or Rights											$ 0.03
Series A Warrants [Member] | Subsequent Event [Member] | Intracoastal Capital, LLC [Member]
Stock Issued During Period, Shares, Warrants Exercised			80,804	158,240	79,998		15,951
Class of Warrant or Right, Exercised During Period			100,000	100,000	100,000		20,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.0334	$ 0.0334	$ 0.0334		$ 0.0334